Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN201
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CN201 is a novel investigational bispecific antibody that targets both CD3 and CD19, functioning as a T-cell engager to direct T cells to eliminate B cells. It is an IgG4-based, humanized protein with a silenced Fc fragment designed to reduce cytokine release syndrome while maintaining potent T-cell mediated cytotoxicity. The drug is being developed for the treatment of B-cell associated diseases, including relapsed or refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL), and has shown promising early clinical activity in these indications. Merck acquired global rights to CN201 from Curon Biopharmaceutical in 2024 and plans further development for both malignant and autoimmune B-cell disorders[1][2][4][8].
- Other names
- recombinant humanized anti-CD3/CD19 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CN201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN201.